Stay updated on Daratumumab Therapy for Refractory AL Amyloidosis Clinical Trial
Sign up to get notified when there's something new on the Daratumumab Therapy for Refractory AL Amyloidosis Clinical Trial page.

Latest updates to the Daratumumab Therapy for Refractory AL Amyloidosis Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2; this is a minor version change and does not affect study content or user actions—To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedA banner states that due to a lapse in government funding, the information on the site may be out of date and transactions may be delayed; it also notes the NIH Clinical Center is open and directs readers to opm.gov for status updates.SummaryDifference0.4%

- Check34 days agoChange DetectedNo significant changes detected in core study details, eligibility criteria, or primary outcomes; any updates appear to be minor formatting or layout adjustments that do not affect the information presented. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check63 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference4%

- Check70 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

- Check84 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2, and the 'Back to Top' link was removed.SummaryDifference0.2%

Stay in the know with updates to Daratumumab Therapy for Refractory AL Amyloidosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab Therapy for Refractory AL Amyloidosis Clinical Trial page.